| 3.79 0.1 (2.71%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.03 | 1-year : | 6.16 |
| Resists | First : | 4.31 | Second : | 5.28 |
| Pivot price | 3.57 |
|||
| Supports | First : | 2.75 | Second : | 2.28 |
| MAs | MA(5) : | 3.66 | MA(20) : | 3.67 |
| MA(100) : | 7.47 |
MA(250) : | 11.05 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 61.3 |
D(3) : | 56.5 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 22.39 | Low : | 2.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BFRI ] has closed below upper band by 29.2%. Bollinger Bands are 63.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.01 - 4.03 | 4.03 - 4.04 |
| Low: | 3.44 - 3.46 | 3.46 - 3.47 |
| Close: | 3.57 - 3.6 | 3.6 - 3.63 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Wed, 22 Nov 2023
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Tue, 14 Nov 2023
Biofrontera Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Mon, 13 Nov 2023
The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43% - Simply Wall St
Sat, 11 Nov 2023
Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% Plummet - Yahoo Finance
Sat, 11 Nov 2023
Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript - Yahoo Finance
Thu, 09 Nov 2023
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 43 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -20.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -78.7 % |
| Operating Margin | -49.7 % |
| Return on Assets (ttm) | -30.8 % |
| Return on Equity (ttm) | -223.8 % |
| Qtrly Rev. Growth | 105.8 % |
| Gross Profit (p.s.) | 8.87 |
| Sales Per Share | 22.11 |
| EBITDA (p.s.) | -14.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 4.98 |
| Price to Sales | 0.17 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|